Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 0.66 |
| ▸ | HTR2A | P28223 | 5/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990979 | 0.79 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22990956 | 0.78 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22991034 | 0.78 | DRD3 (1.00) | DRD3DRD2HTR2A | |
| SCHEMBL22990901 | 0.78 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21040985 | 0.77 | DRD3 (0.75) | DRD3DRD2HTR2A | |
| SCHEMBL21041466 | 0.77 | DRD3 (0.64) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21040963 | 0.76 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22990972 | 0.76 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21040623 | 0.76 | DRD3 (0.64) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22892399 | 0.76 | DRD3 (0.81) | DRD3DRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047315-A1 | CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047315-A1 | CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | DRD3, DRD2, DRD1 | DRD3 1/4885DRD2 2/4885HTR2A 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.